[go: up one dir, main page]

EA202193257A1 - Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы - Google Patents

Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы

Info

Publication number
EA202193257A1
EA202193257A1 EA202193257A EA202193257A EA202193257A1 EA 202193257 A1 EA202193257 A1 EA 202193257A1 EA 202193257 A EA202193257 A EA 202193257A EA 202193257 A EA202193257 A EA 202193257A EA 202193257 A1 EA202193257 A1 EA 202193257A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
breast cancer
application
cancer treatment
leuprolide acetate
Prior art date
Application number
EA202193257A
Other languages
English (en)
Inventor
Джон Миддлтон
Авинаш Нангия
Джон Артур Маклейн
Терри Л. Мортон
Original Assignee
Толмар Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Толмар Интернэшнл Лимитед filed Critical Толмар Интернэшнл Лимитед
Publication of EA202193257A1 publication Critical patent/EA202193257A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Композиции и методы подавления функции яичников у субъектов с гормон-рецептор-положительным раком молочной железы.
EA202193257A 2019-05-27 2020-05-26 Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы EA202193257A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27
PCT/IB2020/054984 WO2020240417A1 (en) 2019-05-27 2020-05-26 Leuprolide acetate compositions and methods of using the same to treat breast cancer

Publications (1)

Publication Number Publication Date
EA202193257A1 true EA202193257A1 (ru) 2022-03-10

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193257A EA202193257A1 (ru) 2019-05-27 2020-05-26 Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы

Country Status (17)

Country Link
US (1) US20220265760A1 (ru)
EP (1) EP3975990A1 (ru)
JP (1) JP2022535694A (ru)
KR (1) KR20220041782A (ru)
CN (1) CN114144169A (ru)
AR (1) AR119021A1 (ru)
AU (1) AU2020284587A1 (ru)
BR (1) BR112021023904A2 (ru)
CA (1) CA3141456A1 (ru)
EA (1) EA202193257A1 (ru)
IL (1) IL288503A (ru)
MX (1) MX2021014540A (ru)
PH (1) PH12021552976A1 (ru)
SG (1) SG11202112888RA (ru)
TW (1) TWI757753B (ru)
UY (1) UY38717A (ru)
WO (1) WO2020240417A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4135830T3 (pl) 2020-12-23 2025-01-07 Tolmar International Limited Układy dla zespołów zaworów strzykawek mieszających i sposoby
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
BR9507313A (pt) 1994-04-08 1997-10-07 Atrix Lab Inc Composição liquida de liberação adequada para a formação de um implante de liberação controlada sistema polimérico curativo filmico microporoso biodegradável precursor de implante de liberação controlada para a implantação em um indivíduo polímero termoplástico solvente orgánico composicão de pré-polimero liquido componente de liberação controlada agente ativo uso da composição liquida de liberação e processos para forma um implante microporoso de liberação prolongada e para liberar um agente ativo em um individuo
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
KR20150017777A (ko) * 2006-01-18 2015-02-17 포시에이서 파마슈티컬스 인코포레이티드 안정성이 강화된 약학 조성물
HRP20231117T3 (hr) * 2007-02-15 2023-12-22 Tolmar International Limited Poli-(laktid-ko-glikolid) sa smanjenim efektom naglog oslobađanja
PL4241849T3 (pl) * 2011-10-14 2025-01-13 F. Hoffmann-La Roche Ag Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2

Also Published As

Publication number Publication date
TWI757753B (zh) 2022-03-11
EP3975990A1 (en) 2022-04-06
US20220265760A1 (en) 2022-08-25
CN114144169A (zh) 2022-03-04
WO2020240417A1 (en) 2020-12-03
TW202110472A (zh) 2021-03-16
AU2020284587A1 (en) 2022-01-06
CA3141456A1 (en) 2020-12-03
UY38717A (es) 2020-11-30
IL288503A (en) 2022-01-01
KR20220041782A (ko) 2022-04-01
JP2022535694A (ja) 2022-08-10
MX2021014540A (es) 2022-04-12
BR112021023904A2 (pt) 2022-02-01
PH12021552976A1 (en) 2022-07-04
AR119021A1 (es) 2021-11-17
SG11202112888RA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CL2019003266A1 (es) Anticuerpos anti-sirpalfa.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PE20210288A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA202092306A1 (ru) Анти-cd24 композиции и их применения
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
EA201892294A1 (ru) Антитела и композиции против tim-3
MX2021014286A (es) Proteinas multiespecificas.
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
CL2017003131A1 (es) Terapia de combinación para el tratamiento de cáncer
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
MX2019010440A (es) Proteinas de union a antigeno anti-tigit y metodos de uso de las mismas.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
MX2022002682A (es) Anticuerpos anti-cd73.
EA201592203A1 (ru) Способы лечения таупатии
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
IL280145A (en) Methods and compositions using recombinant dendritic cells for cancer therapy